TY - JOUR AU - Cunningham, Evan B. AU - Hajarizadeh, Behzad AU - Dalgard, Olav AU - Amin, Janaki AU - Hellard, Margaret AU - Foster, Graham R. AU - Bruggmann, Philip AU - Conway, Brian AU - Backmund, Markus AU - Robaeys, Geert AU - Swan, Tracy AU - Marks, Philippa S. AU - Quiene, Sophie AU - Applegate, Tanya L. AU - Weltman, Martin AU - Shaw, David AU - Dunlop, Adrian AU - Bruneau, Julie AU - Midgard, HÃ¥vard AU - Bourgeois, Stefan AU - Thurnheer, Maria Christine AU - Dore, Gregory J. AU - Grebely, Jason AU - on behalf of the ACTIVATE Study Group PY - 2017 DA - 2017/06/13 TI - Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study JO - BMC Infectious Diseases SP - 420 VL - 17 IS - 1 AB - The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. SN - 1471-2334 UR - https://doi.org/10.1186/s12879-017-2517-3 DO - 10.1186/s12879-017-2517-3 ID - Cunningham2017 ER -